HTGMQ — HTG Molecular Diagnostics Balance Sheet
0.000.00%
HealthcareHighly SpeculativeMicro Cap
- $0.00m
- $0.33m
- $6.37m
Annual balance sheet for HTG Molecular Diagnostics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
C2018 December 31st | 2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 31.1 | 33 | 28.7 | 21.9 | 12.2 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 5.01 | 3.16 | 1.59 | 2.09 | 1.42 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 38 | 41.4 | 32.9 | 27.2 | 15.7 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 2.37 | 3.45 | 2.24 | 2.46 | 1.61 |
Other Long Term Assets | |||||
Total Assets | 43.8 | 45.1 | 35.2 | 30.5 | 17.8 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 7.02 | 8.9 | 7.24 | 9.94 | 8.27 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 22.7 | 21.1 | 20.7 | 20.1 | 12.4 |
Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 21.1 | 24 | 14.5 | 10.4 | 5.39 |
Total Liabilities & Shareholders' Equity | 43.8 | 45.1 | 35.2 | 30.5 | 17.8 |
Total Common Shares Outstanding | |||||
Total Preferred Shares Outstanding |